迈威生物：董事长兼总经理刘大涛因涉嫌短线交易被立案调查

Core Viewpoint - The chairman and general manager of Maiwei Biotechnology, Liu Datao, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading, but this investigation is focused solely on Liu and will not significantly impact the company's daily operations [1] Company Summary - Liu Datao has received a notice of investigation from the CSRC due to allegations of short-term trading [1] - The investigation is specifically targeting Liu Datao as an individual and is not expected to have a major effect on the company's operational activities [1] - The company will continue to monitor the situation and fulfill its information disclosure obligations [1]